Knowledge, practice and acceptability of HPV vaccine by mothers of adolescent girls in Ilorin, Nigeria


Background: Human Papilloma Virus (HPV) is a sexually transmitted cause of carcinoma of the cervix. An important determinant of the success of a primary preventive strategy like HPV vaccination is the knowledge and willingness of parents to vaccinate adolescents before sexual debut.

Materials and methods of study: A cross sectional descriptive survey of mothers of girls in 8 secondary schools in Ilorin was carried out from February to April 2015. Schools were selected using multi staged sampling. Descriptive and inferential statistics were performed with Chi Square and ANOVA.

Results: There were 470 questionnaires returned for analysis out of 600, giving a response rate of 78.3%. One hundred and sixty-one (34.3%) knew HPV to be sexually transmitted infection and 40.4% knew it was the cause of cervical cancer. While 35.1% were aware of HPV vaccine, only 1.9% had ever vaccinated their children.
Less than half (44.9%) were willing to vaccinate their children. Women with good knowledge of HPV and cervical cancer were more willing to vaccinate their children than women with poor knowledge (P <0.001).

Conclusion: There is poor knowledge of HPV and practice of vaccination among mothers in llorin. Willingness of mothers to vaccinate their daughters is suboptimal. Mother’s knowledge is an important determinant of HPV vaccination of adolescents.

[1] Parkin DM, Bray F. The burden of HPV- related cancers. Vaccine 2006;24:11-25.

[2] WHO/ICO. Information on HPV and Cervical Cancer (HPV Information Centre). Summary report on HPV and Cervical Cancer statistics in Nigeria. 2007 [cited 2013 Feb 12]. Available

[3] Kolawole AO. Cervical Cancer Prevention in Nigeria: Issues Arising. Internet Journal of Gynecology and Obstetrics. 2012 Jan[cited Feb 11];16(1). DOI: 10.5580/2b20.Available from at:

[4] Adesina K, Saidu R, Aboyeji A, Fawole A, Olarinoye A, Ibrahim K. Factors contributing to low cervical cancer screening in a population at risk. Nig J Health Sci.2010;10:21- 25.

[5] Ault KA. Effect of prophylactic human papillomavirus L1 virus-like particle vaccine on risk of cervical intraepithelial neoplasia grade 2,grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861–1868.

[6] Nnodu O, Erinosho L, Jamda M, Olaniyi O, Adelaiye R,Lawson L et al. Knowledge and Attitudes towards Cervical Cancer and Human Papillomavirus: A Nigerian Pilot Study. African Journal of Reproductive Health 2010; 14:95-108.

[7] Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Xavier Bosch F ,Franco E . Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:604–15.

[8] Moraros J , Bird Y, Barney D.D ,King S.C ,Banegas M, Suarez-Toriello E. A Pilot Study: HPV Infection Knowledge & HPV Vaccine Acceptance among Women Residing in Ciudad Juárez, México. Californian Journal of Health Promotion 2006; 4:177-186.

[9] Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928–1943.

[10] D. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161–2170.

[11] Thomas JO, Hererro R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A et al. Prevalence of Human Papilloma Virus Infection in women in Ibadan,Nigeria: a population-based study. Br J Cancer 2004;90:638-645.

[12] Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55: 244-265.

[13] Becker-Dreps S, Otieno WA, Brewer NT, Agot K, Smith JS.HPV vaccine acceptability among Kenyan women. Vaccine2010;28: 4864–4867.

[14] Liu FW, Vwalika B, Hacker MR, Allen S, Awtrey CS. Cervical Cancer and HPV Vaccination: Knowledge and Attitudes of Adult Women in Lusaka, Zambia. Journal of Vaccines & Vaccination 2012 doi: 10.4172/2157-7560.1000138

[15] Francis SA, Nelson J, Liverpool J, Soogun S, Mofammere N, Thorpe RJ. Examining attitudes and knowledge about HPV and cervical cancer risk among female clinic attendees in Johannesburg, South Africa. Vaccine 2010;28: 8026–8032

[16] Coleman MA, Levison J, Sangi-Haghpeykar H . HPV vaccine acceptability in Ghana, West Africa. Vaccine.2011; 29: 3945–3950.

[17] Wamai RG, Ayissi CA, Oduwo GO, Perlman S, Welty E, Manga S et al. Assessing the effectiveness of a community-based sensitization strategy in creating awareness about HPV, cervical cancer and HPV vaccine among parents in North West Cameroon. Journal of community health.2012; 37: 917–926.

[18] Ayissi CA, Wamai RG, Oduwo GO, Perlman S, Welty E, Welty T et al. Awareness, Acceptability and Uptake of Human Papilloma Virus Vaccine among Cameroonian School-Attending Female Adolescents. Journal of community health2012; 37: 1127– 1135. doi: 10.1007/s10900-012-9554-z

[19] Perlman S, Wamai RG, Bain PA, Welty T, Welty E, Ogembo JG. Knowledge and of HPV vaccine and acceptability to vaccinate in sub-Saharan Africa: a systematic review. PLoS ONE2014; 9: e90912. doi:10.1371/journal.pone.0090912.

[20] Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Centers for Disease Control and Prevention (CDC); Advisory Committee on munization Practices (ACIP) Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm

[21] Fisher WA, Laniado H, Shoval H, Hakim M, Bornstein J. Barriers to human papillomavirus vaccine acceptability in Israel. Vaccine 2013; 31: 153-157.